Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 [Yahoo! Finance]
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025
IRIDEX (NASDAQ:IRIX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management [Yahoo! Finance]
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management